Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Biologics Center May Get Its Day In PDUFA VII

Executive Summary

Multiple stakeholders call for CBER to receive more prescription drug user fee funds amid growing cell and gene therapy popularity.

You may also be interested in...



Full Extent Of Clinical Trial Damage May Be Unknown Until Pandemic Ends, CBER’s Peter Marks Says

More patient-centric trial designs also may be coming due to pandemic-related advances, Marks says.

PDUFA And Gene Therapy: Bring ‘Fully Baked’ Ideas And ‘Don’t Be Stingy,’ Grogan Tells Developers

Former chief of White House Domestic Policy Council advises cell and gene therapy companies on strategies for promoting enhanced FDA review capabilities as part of Prescription Drug User Fee Act reauthorization negotiations.

PDUFA VII Talks Begin With Similar Goals For Industry, US FDA

Both sides want enhancements to deal with growth in cell and gene therapy, as well as work on regulatory decision tools and finance issues.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel